FOLLOW US

  • facebook
  • twitter
Wed

March 4, 2026

Cellectis, AstraZeneca IP Suit

America September 27, 2025

Cellectis, AstraZeneca Hit with IP Suit Over Gene-Editing Technology

A Massachusetts-based biotech says two pharmaceutical giants are trampling its intellectual property. Factor Bioscience Inc. filed suit Friday in Delaware…

By Rihem Akkouche

MaxCyte Buys SeQure Dx For Up To $7M

America January 30, 2025

MaxCyte Buys SeQure Dx for Up to $7M

MaxCyte Inc., a leading cell therapy and gene editing company, announced Thursday that it has acquired SeQure Dx, a specialized…

By Rihem Akkouche

Gene-Editing Innovator Metagenomi Aims to Make a Splash with $100M IPO

America February 5, 2024

Metagenomi Inc. Dives into IPO Wave, Aims for $100M Raise

Emeryville-based biotech firm, Metagenomi Inc., makes headlines as it dives into the IPO market, eyeing a substantial $100 million raise…

By Rochdi Rais

Signup for the USA Herald
exclusive Newsletter